NHC Communications, Inc. manufactures network switching and test equipment for local telecom service providers, corporations and multi-tenant buildings. It also offers the XPoint product line geared for smaller network applications. The company was founded in 1986 and is headquartered in Mount-Royal, Canada

TesoRx is a virtual pharmaceutical company developing and commercializing pharmaceutical products. The company engages in developing and commercializing pharmaceutical products. It develops TSX-002, an oral therapeutic testosterone formulation for use in testosterone deficiency in men. The company was incorporated in 2010 and is based in Menlo Park, California.

Oncoxx Biotech is a cancer biotech company founded in 2012 as partnership between Chieti University Research Center and private entrepreneurs. Oncoxx Biotech academic settings allow competitive R&D and clinical experimentation costs. The company has already generated two new anti-Trop-2 monoclonal antibodies as anti-cancer agents.

LIPAC Oncology is a clinical-stage drug delivery company focused on developing unique localized therapies to treat cancer in challenging parts of the body. It’s breakthrough technology addresses shortcomings of current treatments for Bladder Cancer, Upper Tract Urothelial Carcinoma and Stage II/III Ovarian Cancer.

WALMARK as manufactures vitamins, minerals and dietary supplements. Its product portfolio includes premium joint care brands ArthroStop and Proenzi, range of male and female urology brands Prostenal, as well as children’s multi-vitamin brand Martánci. The company was founded by Adam Walach, Mariusz Walach, and Waldemar Walach on July 30, 1990 and is headquartered in Trinec, Czech Republic.

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

TARIS Biomedical develops new therapies designed for the treatment of difficult-to-treat bladder diseases. The company's system is designed to continuously release drugs in the bladder over weeks to months and is deployed and retrieved using minimally-invasive, in-office procedures, enabling drug release to be tailored to match the needs of each disease.

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Hitachi Chemical Co. America Ltd., a subsidiary of Showa Denko K.K., is a company headquartered in Cupertino, CA, that engages in the manufacture and sale of electronic materials, functional films, semiconductor materials, automotive products and others.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

DUSA Pharmaceuticals, Inc.® (NASDAQGM: DUSA) is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator. Levulan Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% in combination with the BLU-U is approved by the U.S. Food and Drug Administration for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. Actinic Keratosis is the most frequently diagnosed skin disease by U.S. dermatologists. PDT is a two part process in which the target cells are made extremely sensitive to light and then exposed to blue light, which destroys the cells. The BLU-U, as a stand alone device, uses light to treat mild to moderate inflammatory acne. DUSA is based in Wilmington, MA.

40 J's LLC provides medical instruments and technologies services. Its products include female sensuality gel and female sensuality gel custom formulations. The company is headquartered in Cincinnati, OH.

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Affinergy LLC develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces. The firm focuses on developing coatings and medical devices for the orthopedic and cardiovascular markets. It constructs bifunctional peptide linkers that selectively immobilize proteins, cells, and therapeutics onto biomaterial surfaces. The firm offers its products for orthopedics, cardiovascular, and tissue engineering; and drug delivery and stem cells markets. The company was founded by Daniel J. Kenan, Jonathan Gindes, and Mark W. Grinstaff in 2002 and is headquartered in Durham, NC.